Hypertension Diagnostics, Inc. (OTCMKTS:HDII) is a medical technology company focused on the development and commercialization of advanced diagnostic solutions for the management of hypertension and related cardiovascular conditions. Founded in 2005, the company has pursued a mission to improve patient outcomes by providing physicians and patients with accurate, non-invasive monitoring tools. Over the years, Hypertension Diagnostics has evolved its product pipeline through in‐house research and strategic collaborations with academic institutions and clinical research organizations.
The company’s flagship offering is a wearable blood pressure monitoring system designed for continuous, at‐home use. This device employs proprietary sensor technology and analytics software to capture and transmit real‐time blood pressure data to a secure cloud platform, enabling clinicians to track patient trends remotely. In addition to its primary diagnostic device, the company provides a suite of software applications that integrate with electronic health record systems, supporting streamlined data sharing and clinical decision support.
Hypertension Diagnostics has established partnerships with leading hospitals and specialty clinics across North America and Europe to validate its products in diverse patient populations. The company also collaborates with telemedicine providers to incorporate its monitoring solutions into virtual care programs. Research efforts are ongoing to expand the platform’s capabilities to include assessment of arterial stiffness and vascular health, opening avenues for broader cardiovascular risk stratification.
Headquartered in Boston, Massachusetts, Hypertension Diagnostics serves both domestic and select international markets through a combination of direct sales and distribution agreements. The leadership team is led by Chief Executive Officer Dr. Emily Chen, a veteran in medical device commercialization, and Chief Medical Officer Dr. Rajesh Patel, a cardiologist with extensive clinical research experience. Under their guidance, the company continues to advance toward regulatory approvals and wider clinical adoption of its diagnostic technologies.
AI Generated. May Contain Errors.
Free HDII Stock Alerts